Brokerages expect Regenxbio Inc (NASDAQ:RGNX) to report sales of $39.67 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Regenxbio’s earnings, with estimates ranging from $11.80 million to $67.54 million. Regenxbio posted sales of $40.78 million in the same quarter last year, which suggests a negative year-over-year growth rate of 2.7%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 26th.

On average, analysts expect that Regenxbio will report full-year sales of $59.12 million for the current year, with estimates ranging from $35.20 million to $91.00 million. For the next financial year, analysts forecast that the company will report sales of $211.88 million, with estimates ranging from $169.67 million to $286.80 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Regenxbio.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.03). The firm had revenue of $14.70 million during the quarter, compared to the consensus estimate of $7.46 million. Regenxbio had a negative net margin of 99.57% and a negative return on equity of 18.74%. The firm’s quarterly revenue was up 177.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.56) earnings per share.

RGNX has been the topic of a number of recent research reports. Leerink Swann upgraded Regenxbio from an “underperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call. Evercore ISI reiterated a “buy” rating and issued a $65.00 price objective on shares of Regenxbio in a research report on Monday, November 11th. Chardan Capital set a $150.00 price objective on Regenxbio and gave the company a “buy” rating in a research report on Wednesday, September 4th. Svb Leerink upgraded Regenxbio from an “underperform” rating to a “market perform” rating and decreased their price objective for the company from $38.00 to $37.00 in a research report on Tuesday, August 20th. Finally, Zacks Investment Research lowered Regenxbio from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Regenxbio has an average rating of “Buy” and a consensus price target of $72.38.

RGNX traded up $0.78 during mid-day trading on Friday, reaching $38.19. The stock had a trading volume of 358,200 shares, compared to its average volume of 556,272. The stock has a market capitalization of $1.37 billion, a P/E ratio of 16.05 and a beta of 0.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.49 and a current ratio of 11.49. The firm’s fifty day simple moving average is $37.82 and its two-hundred day simple moving average is $42.10. Regenxbio has a 52 week low of $30.38 and a 52 week high of $65.62.

In other news, SVP Patrick J. Christmas sold 5,486 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $42.00, for a total value of $230,412.00. Following the transaction, the senior vice president now directly owns 8,058 shares in the company, valued at approximately $338,436. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $39.75, for a total value of $397,500.00. Following the completion of the transaction, the chief executive officer now owns 251,000 shares in the company, valued at $9,977,250. The disclosure for this sale can be found here. 13.80% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Berman Capital Advisors LLC boosted its position in shares of Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 333 shares during the last quarter. NEXT Financial Group Inc bought a new position in shares of Regenxbio in the 2nd quarter worth $69,000. Royal Bank of Canada boosted its position in shares of Regenxbio by 36.2% in the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 1,040 shares during the last quarter. Virginia Retirement Systems ET AL bought a new position in shares of Regenxbio in the 2nd quarter worth $216,000. Finally, Ellington Management Group LLC bought a new position in shares of Regenxbio in the 2nd quarter worth $216,000. Institutional investors and hedge funds own 79.17% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: How to read a candlestick chart

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.